Company Profile
Lexicon Pharmaceuticals
Company Overview
Lexicon is a fully integrated biopharmaceutical company located in The Woodlands, Texas and Basking Ridge, New Jersey that is applying a unique approach to gene science, based on Nobel Prize-winning technology, to discover and develop precise medicines for patients with serious, chronic conditions.
Through its Genome5000™ program, Lexicon scientists have studied the role and function of nearly 5,000 genes over the last 20 years and have identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon has a pipeline of promising drug candidates in clinical and pre-clinical development in oncology, diabetes and metabolism.
In August of 2015, Lexicon announced that its pivotal TELESTAR Phase 3 clinical trial met its primary endpoint, showing the benefit of oral telotristat etiprate in treating cancer patients with carcinoid syndrome that is not adequately controlled by the current standard of care. Lexicon received Fast Track designation and Orphan Drug status for telotristat etiprate from the U.S. Food and Drug Administration (FDA) in 2008 and 2012, respectively. Lexicon is also developing sotagliflozin as an oral treatment for type 1 diabetes. Lexicon is currently conducting Phase 3 development of sotagliflozin in type 1 diabetes and an additional Phase 2 clinical trial of sotagliflozin. Lexicon announced a collaboration and partnership for the development and commercialization of sotagliflozin.Lexicon employees are inspired by the idea that their work can improve patients' lives and we know that our employees are important to the success of our mission.
We are dedicated to making Lexicon a great place to work by providing employees with the benefits, services, and programs which will allow them to reach their full potential.
Notable Accomplishments / Recognition
Through its Genome5000™ program, Lexicon scientists have studied the role and function of nearly 5,000 genes over the last 20 years and have identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon has a pipeline of promising drug candidates in clinical and pre-clinical development in oncology, diabetes and metabolism. In August of 2015, Lexicon announced that its pivotal TELESTAR Phase 3 clinical trial met its primary endpoint, showing the benefit of oral telotristat etiprate in treating cancer patients with carcinoid syndrome that is not adequately controlled by the current standard of care. Lexicon received Fast Track designation and Orphan Drug status for telotristat etiprate from the U.S. Food and Drug Administration (FDA) in 2008 and 2012, respectively. Lexicon is also developing sotagliflozin as an oral treatment for type 1 diabetes. Lexicon is currently conducting Phase 3 development of sotagliflozin in type 1 diabetes and an additional Phase 2 clinical trial of sotagliflozin. Lexicon announced a collaboration and partnership for the development and commercialization of sotagliflozin.